Stay updated on Precision 1 Clinical Trial: Nab-sirolimus in TSC1/TSC2 Gene Tumors
Sign up to get notified when there's something new on the Precision 1 Clinical Trial: Nab-sirolimus in TSC1/TSC2 Gene Tumors page.

Latest updates to the Precision 1 Clinical Trial: Nab-sirolimus in TSC1/TSC2 Gene Tumors page
- Check3 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference0.8%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check46 days agoChange DetectedThe page has undergone significant content removal, particularly regarding a Phase 2 clinical trial for nab-sirolimus, which included detailed eligibility criteria and treatment protocols for patients with malignant solid tumors. The revision number has also been updated from v2.14.4 to v2.15.0.SummaryDifference27%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check61 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check97 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
Stay in the know with updates to Precision 1 Clinical Trial: Nab-sirolimus in TSC1/TSC2 Gene Tumors
Enter your email address, and we'll notify you when there's something new on the Precision 1 Clinical Trial: Nab-sirolimus in TSC1/TSC2 Gene Tumors page.